VistaGen Therapeutics (VTGN)
(Delayed Data from NSDQ)
$3.84 USD
-0.07 (-1.79%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $3.81 -0.03 (-0.78%) 7:58 PM ET
5-Strong Sell of 5 5
F Value F Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
VTGN 3.84 -0.07(-1.79%)
Will VTGN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for VTGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VTGN
Does VistaGen Therapeutics, Inc. (VTGN) Have the Potential to Rally 160% as Wall Street Analysts Expect?
Immunocore Holdings PLC Sponsored ADR (IMCR) Moves 6.9% Higher: Will This Strength Last?
VTGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
How Vistagen (VTGN) Stock Stands Out in a Strong Industry
Biotech Stock Roundup: SAGE, GRTX Plunge on Setback, REGN to Buy DBTX & More News
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates
Other News for VTGN
Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine
Vistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year
Biotech Alert: Searches spiking for these stocks today
VistaGen Therapeutics Inc. at Risk: Market Turmoil and Economic Instability Threaten Financial Stability
VTGN Stock Earnings: VistaGen Therapeutics Beats EPS, Misses Revenue for Q4 2024